Farmas USA

rgls

halt

madre de dios

regular regular

Pipeline Update

RG-012 for the treatment of Alport Syndrome: The Company has completed dosing of RG-012 in its Phase I multiple ascending dose (MAD) study and has selected the dose for the upcoming Phase II HERA and renal biopsy studies, which is expected to commence mid-2017.  Preliminary data from the MAD study indicated that RG-012 was well tolerated with no serious adverse events (SAEs) reported in any subjects. The plasma PK profile of RG-012 was in-line with expectations, with a dose dependent increase in plasma exposure seen across the three dose groups. Data from the renal biopsy study is anticipated by year-end 2017, and interim data from the Phase II HERA study is anticipated in mid-2018.

Q1 Financial Results

Cash Position:  Cash, cash equivalents and short-term investments were $57.5 million at March 31, 2017, compared with $76.1 million at December 31, 2016.

Research and Development (R&D) Expenses:  R&D expenses were $15.8 million for the quarter ended March 31, 2017, compared to $16.8 million for the quarter ended March 31, 2016. The decrease in R&D expenses was primarily driven by a decrease in spend on the RG-101 program due to the FDA clinical hold, partially offset by an increase in internal costs attributable to our preclinical pipeline.

General and Administrative (G&A) Expenses:  G&A expenses were $4.0 million for the quarter ended March 31, 2017, compared to $5.1 million for the quarter ended March 31, 2016.

Revenue: Revenue was less than $0.1 million for the quarter ended March 31, 2017, compared to $0.5 million for the quarter ended March 31, 2016.

Net Loss:  Net loss was $20.0 million, or $0.38 per share (basic and diluted), for the quarter ended March 31, 2017, compared to a net loss of $21.2 million, or $0.40 per share (basic and diluted), for the quarter ended March 31, 2016.

Pues vaya velica semanal para maquillar mañana, no ?

IBB

rgls

vendidas, fuera plano sin profits, a otra cosa.

pffffffff.

TGTX

ER

http://ir.tgtherapeutics.com/releaseDetail.cfm?ReleaseID=1025060

Catalizadores, los previstos. Quemado de caja, doblándose, pero vamos, normal en fases 3 y una vez ya se centran en la comercialización.

PBYI

Tienen un buen lío montado. Se va un Vice Presidente justa a 2 semanas de Adcom. Dicen que es por su salud, pero las dudas han aflorado. Ayer -11% en AH (y en PM sigue bajando...). Opinión bastardo:

https://www.thestreet.com/story/14120658/1/a-top-puma-bio-exec-resigns-ahead-of-fda-panel-analysts-defend-with-conflicting-stories.html

NVIV

Hundimiento a 2,65

Analyst Reni Benjamin sees risks increasing and comments "While we continue to believe that the company’s Neuro-Spinal Scaffold appears to have demonstrated therapeutic effect in SCI patients, we are becoming more cautious about the ultimate approvability of the product given the reversions seen in the two patients as well as the uncertainty surrounding the company’s proposed control arms for the INSPIRE study".

https://www.streetinsider.com/Analyst+PT+Change/Raymond+James+Downgrades+InVivo+Therapeutics+%28NVIV%29+to+Outperform/12863612.html

RGLS

He intentado entrar cuando estaba a 1,10 y no ha entrado ni una.

Los problemas del modo movil y mas con Bankinter.

RGLS, me ha salido bien la jugada. vendí ayer en $1,70 las que había comprado a $1,15 hace meses y hoy he vuelto a comprar a $1,15. Como dije, esta la tengo solo para tradearla, ya que El programa RG 101 en mi opinión lo van a parar antes o después. no tiene mucho sentido mantenerlo y ese hold parece permanente. Además no me fío de Stelios y que decir de la dimisión del CEO...

ayer vendí en after cagandome en la p..a M....e y maldiciendo, este temperamento mio no casa con esta m....a, pero es lo que hay, al final el error es mio, me pudo el ansia viva  ;)

https://youtu.be/gc9SYGbH3d8